Trial reportLung cancer (Amsterdam, Netherlands)2012
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
Trial report in Lung cancer (Amsterdam, Netherlands), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 75 citations in OpenAlex.
- Trial
- A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).Investigational new drugs · 2013Trial
- Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.Lung cancer (Amsterdam, Netherlands) · 2012Trial
- Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Trial
- From biology to therapy: current standards and emerging strategies in pleural mesothelioma.Frontiers in oncology · 2026Review
- The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions.Cancers · 2025Review
- Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?International journal of molecular sciences · 2023Review
- Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.Cell reports. Medicine · 2023Article
- Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow.Translational lung cancer research · 2022Article
- Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.Translational lung cancer research · 2020Review
- Antiangiogeneic Strategies in Mesothelioma.Frontiers in oncology · 2020Review
- Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.Molecular therapy. Nucleic acids · 2019Review
- Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.Frontiers in oncology · 2019Review
- The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy.Frontiers in oncology · 2019Review
- Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.International journal of molecular sciences · 2018Review
- Novel systemic therapy against malignant pleural mesothelioma.Translational lung cancer research · 2017Review
- Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.OncoTargets and therapy · 2017Review
- Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Review
- Malignant pleural mesothelioma: an update on diagnosis and treatment options.Therapeutic advances in respiratory disease · 2016Review
- A new standard for malignant pleural mesothelioma.Lancet (London, England) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
introductionThe Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant mesothelioma and to evaluate potential biomarkers of disease response (CALGB 30107).
methodsTreatment consisted of vatalanib 1250 mg given orally once daily. CT scans were obtained at baseline and every 6 weeks thereafter. Baseline serum levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), thrombospondin-1 (TSP-1), and mesothelin were obtained. The primary endpoint was 3-month progression-free survival (PFS).
resultsForty-seven patients enrolled at 19 centers. The median age was 75 years, and the majority of patients (79%) had an ECOG performance status of 1. Tumors were classified as epithelial (77%), sarcomatoid (10%), or mixed (9%) histology. Toxicity was mild; the most common grade 3/4 adverse events were neutropenia (2%), nausea (15%), elevated alanine aminotransferase (11%), hypertension (2%), and gastrointestinal bleeding (2%). Partial responses were observed in 6% of patients and stable disease in 72% of patients. The 3-month PFS rate was 55% (95% CI: 40%, 68%). The median PFS was 4.1 months. Median overall survival was 10.0 months. There was no correlation between serum levels of VEGF, PDGF, TSP-1, or mesothelin and treatment response, PFS, or survival.
conclusionsVatalanib as a single agent with this dose and schedule does not warrant further study in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.